IP Library Granted Patent US 9,642,820
Granted Patent B2
US 9,642,820 · App. 14/568,925 · Granted May 9, 2017

Materials and methods for controlling infections

Inventors: Carolyn L. Twomey (Lawrenceville, GA); Gareth Clarke (Lawrenceville, GA); Samuel J. Zaidspiner (Lawrenceville, GA)
Assignee: INNOVATION TECHNOLOGIES, INC.
A61K31/155A61F13/00063A61K9/0019A61K9/0043A61K9/0073A61K9/0085A61K9/08A61K31/191A61K45/06A61L15/44A61L17/005A61L27/54A61L29/08A61L29/16A61L31/08A61L31/16A61M25/0017A61L2300/206
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,820
App. No.
14/568,925
Granted
May 9, 2017
Kind
B2
Abstract

The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Claims (7)

1. A method for treating a sinus infection in a subject, wherein the infection is caused by methicillin resistant staphylococcus aureus (MRSA) and wherein said method comprises administering to a sinus of the subject an aqueous solution that comprises an active agent that consists essentially of chlorhexidine at a concentration of 0.05% or less.

2. The method of claim 1 , wherein the composition is administered to the sinuses via a nasal irrigation system, a nasal swab, or a neti pot.

3. The method of claim 2 , wherein the chlorhexidine is chlorhexidine gluconate.

4. The method, according to claim 2 , wherein the composition is administered to the sinuses via a nasal irrigation system.

5. The method, according to claim 2 , wherein the composition is administered to the sinuses via a nasal swab.

6. The method, according to claim 2 , wherein the composition is administered to the sinuses via a neti pot.

7. The method, according to claim 2 , used to treat a subject that has been diagnosed with a MRSA infection of the sinus prior to the administration of the chlorhexidine.

Assignments (2)
SECURITY INTEREST Recorded Aug 21, 2024
From: INNOVATION TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 068360/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2016
From: TWOMEY, CAROLYN L.; CLARKE, GARETH; ZAIDSPINER, SAMUEL J.
To: INNOVATION TECHNOLOGIES, INC.
Reel/Frame 038115/0260 →
Continuity (2)
Provisional Application 61915281 · Dec 12, 2013
Related Publication 20150164829A1 · Jun 18, 2015